Claims
- 1. A compound of the formula (Ia): whereinA is alkylene which optionally is intercalated by a hetero atom or phenylene, contains an oxo group, and/or has an unsaturated bond; B is hydrogen, alkyl, aralkyl or acyl; R is COOR1, CH2OR2 or CON(R3)R4; R1 is hydrogen or alkyl; R2 is hydrogen or alkyl; R3 and R4 are independently hydrogen, alkyl, hydroxy or alkylsulfonyl; X1 is a single bond, phenylene, naphthylene, thiophenediyl, indolediyl, or oxazolediyl; X2 is a single bond, —N═N—, —N═CH—, —CH═N—, —CH═N—N—, —CH═N—O—, —C═NNHCSNH—, —C═NNHCONH—, —CH═CH—, —CH(OH)—, —C(Cl)═C(Cl)—, —(CH2)n—, ethynylene, —N(R5)—, —N(R51)CO—, —N(R52)SO2—, —N(R53)CON(R54)—, —CON(R55)—, —SO2N(R56)—, —O—, —S—, —SO—, —SO2—, —CO—, oxadiazolediyl, thiadiazolediyl or tetrazolediyl; X3 is alkyl, alkenyl, alkynyl, aryl, aralkyl, heterocyclic group, cycloalkyl, cycloalkenyl, thiazolinylidenemethyl, thiazolidinylidenemethyl, —CH═NR6 or —N═C(R7)R8; R5, R51, R52, R53, R54, R55 and R56 each are hydrogen or alkyl; R6 is hydrogen, alkyl, hydroxy, alkoxy, carbamoyloxy, thiocarbamoyloxy, ureido or thioureido; R7 and R8 each are independently alkyl, alkyoxy or aryl; and n is 1 or 2; wherein a cyclic substituent may have one to three substituents selected from the group consisting of nitro, alkoxy, sulfamoyl, substituted- or unsubstituted-amino, acyl, acyloxy, hydroxy, halogen, alkyl, alkynyl, carboxy, alkoxycarbonyl, aralkoxycarbonyl, aryloxycarbonyl, mesyloxy, cyano, alkenyloxy, hydroxyalkyl, trifluoromethyl, alkylthio, —N═PPh3, oxo, thioxo, hydroxyimino, alkoxyimino, phenyl and alkylenedioxy or its salt or hydrate thereof, provided that compounds wherein (1) X1 and X2 are a single bond, and X3 is substituted- or unsubstituted-phenyl, or naphthyl; and (2) A is 5-heptenylene, R is COOR1 (R1 is hydrogen or methyl), X1 is 1,4-phenylene, X2 is a single bond, and X3 is unsubstituted phenyl; (3) X1 and X2 are a single bond, X3 is methyl, n-hexyl, 2-cyclohexylethyl, benzyl, phenethyl, or substituted- or unsubstituted-alkenyl; (4) X1 and X2 are a single bond, and X3 is pyridyl; and (5) X1 is a single bond, X2 is —CH═CH—, and X3 is phenyl are excluded.
- 2. The compound of claim 1, its salt or hydrate thereof, wherein X1 and X2 are a single bond, X3 is isoxazolyl, thiadiazolyl, isothiazolyl, morpholyl, indolyl, benzofuryl, dibenzofuryl, dibenzodioxinyl, benzothienyl, dibenzothienyl, carbazolyl, xanthenyl, phenanthridinyl, dibenzoxepinyl, dibenzothiepinyl, cinnolyl, chromenyl, benzimidazolyl, dihydrobenzothiepinyl or dibenzopyranyl.
- 3. The compound of claim 1, its salt or hydrate thereof, wherein X2 is a single bond, X1 is phenylene, X3 is alkenyl, alkynyl, —CH═NR6 or —N═C(R7)R8.
- 4. The compound of claim 1, its salt or hydrate thereof, wherein R is COOR1, X1 is phenylene, thiophenediyl or indolediyl, X2 is a single bond, —N═N—, —CH═CH—, —CONH—, —NHCO—, ethynylene, —N═CH—, —(CH2)n—, —N(R5)—, —O—, —S—, —SO2—, —CO—, oxadiazolediyl or tetrazolediyl; and X3 is phenyl, thiazolinylidenemethyl, thiazolidinylidenemethyl, thienyl, cyclohexyl, 1-cyclohexenyl, n-hexyl, indolyl or benzoxazolyl.
- 5. A composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier thereof.
- 6. A method for treating a PGD2-mediated disease comprising administering to a subject in need thereof, a PGD2 antagonist according to claim 1.
- 7. A method according to claim 6, wherein said PGD2-mediated disease is selected from the group consisting of systemic mastocytosis, disorder of systemic mast cell activation, tracheal contraction, asthma, allergic rhinitis, allergic conjunctivitis, urticaria, injury due to ischemic reperfusion and inflammation.
- 8. A method according to claim 6, wherein said PGD2-mediated disease is nasal occlusion.
Priority Claims (1)
Number |
Date |
Country |
Kind |
7-154575 |
Jun 1995 |
JP |
|
Parent Case Info
This application is a divisional of application Ser. No. 08/973,983, filed Apr. 22, 1998, which is a National Stage of PCT/JP96/01685, filed Jun. 19, 1996.
US Referenced Citations (8)
Foreign Referenced Citations (5)
Number |
Date |
Country |
0 608 847 |
Jun 1982 |
EP |
0 290 285 |
May 1988 |
EP |
61-49 |
Jan 1986 |
JP |
2-62546 |
Dec 1990 |
JP |
06279395 |
Oct 1994 |
JP |
Non-Patent Literature Citations (2)
Entry |
Kohji Hanasaki et al., “Phorbol Ester-Induced Expression of the Common, Low-affinity Binding Site for Primary Prostanoids in Vascular Smooth Muscle Cells,” The Journal of Biological Chemistry, 265(9):4871-4875 (1990), ©The American Society for Biochemistry and Molecular Biology, Inc. |
Kohji Hanasaki et al, “Charaterization of Platelet Thromboxane A2/Prostaglandin H2 Receptor by a Novel Thromboxane Receptor Antagonist, [3H]S-145,” Biochemical Pharmacology, 38(12):2007-2017 (1989), ©Pergamon Press plc. |